Hopkins Communications, PR and Advertising Company, Cork

Back to the News

Bio-medical firm expands pioneering technology and launches its Business Expansion Scheme 09

EnBIO™, headquartered at Fota Point Business Park, Cork, recently copper fastened its reputation as a world-leader in pioneering technology in the bio-medical space with the announcement of the launch of a further new product OsteoZap™.

The company is also launching its Business Expansion Scheme ’09 offering designed to give investors an opportunity to invest in its portfolio of innovative products which are attracting world acclaim. Furthermore, following a recent further investment in EnBIO by Enterprise Ireland under the High Potential Start Up scheme (the third investment in two years) the company, with its experienced team, aims to achieve significant growth in the short term and has increased its workforce by one third in the last year.

Dan Philpott, CEO of EnBIO said: ‘Our core product, CoBlast™ which was launched last year, is already being embraced and validated by several blue-chip companies in the medical devices industry and some non-medical sectors worldwide. Our collaboration with University College Cork, University College Dublin, the University of Ulster and the University of Liverpool has seen CoBlast™ brought to market successfully. The new product we are now launching, OsteoZap™, is designed to prevent infection and bio film formation on orthopaedic implants such as hips and knees, trauma devices, and spinal and dental implants combines long-term infection prevention with the bone integration benefits of the company’s existing OsteoZip™ surface which was launched last year. Several international orthopaedic and dental implant manufacturing companies are interested in the technology and are currently conducting their own evaluation of the technology and its potential application for their implant product offering.’

EnBIO is collaborating with Clemson University in Greenville, South Carolina (which, according to Dan Philpott is ‘the ‘Harvard’ of Bio-Engineering and world renowned in the field of materials science’) and The Steadman Hawkins, Greenville Hospital System on pre-clinical and clinical trials to further validate the OsteoZap™ technology.

Poised to receive another tranche of Business Expansion Scheme funding before year end, the team at EnBIO, led by Philpott, includes Chairman Paddy Caffrey (former VP and Managing Director of Pfizer Ireland Pharmaceuticals), Founder/Director John O’Donoghue (formerly a principle engineer in Guidant/Boston Scientific), Founder and Chief Commercial Officer Joe O’Keeffe (previously founder of hi-tech start-ups Pentus Technologies, SensL, Nanocomms and MV Technologies), and Non Executive Director Pat Forristal who has held a number of senior leadership positions in the Pharmaceutical, Medical Devices and Engineering industries, including Stryker.

Commenting on EnBIO’s progress to date John O’Dea, High Potential Start Up Manager at Enterprise Ireland said: ‘EnBIO’s innovative products are causing considerable interest amongst the medical device manufacturing industry worldwide and we at Enterprise Ireland are confident that this new technology has the potential to be truly ground-breaking. The potential for growth is significant as the EnBio coating technology can also be applied in several other high-value sectors.’
http://www.enbiomaterials.com

John O’Donoghue, Founder and Chief Technical Officer of EnBIO in Cork.